Clinical Trial

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Study acronym: WATCHER
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2022 (before its estimated April 2024 completion). Its status may not reflect the trial's current state.
Summary
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete remission with watchful waiting strategy.
Trial Details
NCT Number NCT05507411
Lead Sponsor Zhejiang Cancer Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 100 participants
Start Date 2022-08-03
Primary Completion 2024-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2022-08-19